Both the rapid plasma reagin (RPR) 18-mm circle card test and the toluidine red unheated serum test (TRUST) 
The rapid plasma reagin (RPR) card test (2, 3) was developed to be more rapid than the Venereal Disease Research Laboratory (VDRL) slide test (4) for the serodiagnosis of syphilis. The RPR card test was intended to eliminate the need for daily antigen preparation, heating of serum before testing, and microscopic examination of test results (3) , which are all required for the VDRL slide test. In addition, the RPR teardrop card test eliminated the need for centrifugation because plasma from finger-stick blood could be used. Although the RPR 18-mm circle card test is a standard test for syphilis for use with serum samples (4) , it has never been recognized as a standard test for use with plasma. A newer macroscopic flocculation test, the toluidine red unheated serum test (TRUST), designed to be a less expensive substitute for the standard RPR card test, has proven in a previous study to be as sensitive and as specific as the RPR card test (D. E. Pettit, S. A. Larsen, J. C. Feeley, C. E. Parham, D. D. Cruce, E. A. Hambie, and M. W. Perryman, submitted for publication). Individuals evaluating the TRUST in the field in underdeveloped countries have suggested that the cost could be further reduced, the test performed more rapidly, and the need for centrifugation eliminated if plasma could be used in place of serum.
In view of the current emphasis on laboratory cost reduction here in the United States, and as an initial evaluation of the use of plasma in the TRUST, we investigated the use of plasma in both the RPR 18-mm circle card test and the TRUST. In this study, we evaluate tests of serum-plasma pairs for comparable sensitivity, specificity, and readability.
MATERIALS AND METHODS
Specimens. Blood was obtained from 306 individuals who attended the DeKalb County (Georgia) Sexually Transmitted Diseases Clinic. A 3-to 4-ml sample of blood was immediately transferred from a 7-ml Vacutainer tube without anticoagulant that was used originally to obtain the blood to a 4-ml Vacutainer tube containing 6.0 mg of EDTA in potassium form. Serumplasma pairs from 132 individuals were tested within 2 h after the blood had been drawn and the plasma or serum had been separated by centrifugation from the cellular constituents of the blood. The 132 plasma samples were further tested at 24-h intervals during 174 individuals were stored unseparated from other blood constituents at 25°C for plasma and 4°C for serum for 18 h. These samples were then centrifuged and then tested. Of these plasma specimens, 33 were tested both before and after centrifugation. Another 39 plasma specimens, which had been separated from cellular products were also tested after storage at -20°C for 1 week. Table 2 . When serum and plasma titers were initially compared, the agreement + 1 dilution was 91.7% (11 of 12) for the RPR card test and 90.9% (10 of 11) for the TRUST. The plasma titers at this time tended to be 1 dilution greater than the serum titers. With storage at 4°C, the titers equalized, and agreement ± 1 dilution was 100%.
Qualitative agreement between plasma and serum samples for each test when the 306 specimen pairs were tested after separation from other blood products and within 18 h is shown in Table 3 . Agreement was 99%o between the serum and plasma pairs for each test. Agreement between the TRUST and RPR card test for serum was 99.3%; agreement between these two tests when plasma was used was 98.7%.
The diagnosis associated with each of the 29 reactive serum specimens is shown in Table 4 . For the 10 cases of untreated syphilis, both tests were reactive whether serum or plasma was used. The reactivities in the 16 cases of treated syphilis were: 16 out of 16 for the RPR card test with plasma, 15 out of 16 for the RPR card test with serum, and 13 out of 16 for the TRUST with both plasma and serum specimens. Therefore, overall agreement of reactivity with diagnosis serum, whereas with plasma the majority of the RPR card test titers were equal to or 1 dilution greater. However, agreement ± 1 dilution between the two tests with both serum and plasma was 100%.
DISCUSSION
Our evaluation indicates that EDTA plasma which has been separated from blood constituents by centrifugation can be used in both the RPR card test and the TRUST without increased difficulty in reading. Like other investigators (1), we noted that roughness increased with storage time at both 4 and 25°C. This increase in roughness was most pronounced after 72 h of storage at 25°C. Even after 24 h at 4°C, however, some roughness was seen. Therefore, we recommend that plasma specimens be tested within 18 h after the blood is collected. If plasma specimens are tested within this period, storage temperature is inconsequential. Separated plasma may also be frozen for up to one week without an additional fibrous clot formihg. Storage of plasma specimens at -20°C for longer than 1 week made specimens unsuitable for testing.
In addition, plasma from uncentrifuged blood may be used for testing in the RPR card test and the TRUST. However, great care should be taken to avoid fibrous material and cellular products when using such plasma. Unseparated plasma should also be tested within 18 h after the blood has been collected. Only plasma from blood collected in EDTA has been evaluated in this manner; therefore, we caution against the testing of plasma when the anticoagulant is other than EDTA or is unknown. Since the effect of a high concentration of EDTA on the outcome of either the RPR card test or the TRUST was not studied, only plasma from collection tubes filled to capacity or near capacity should be used.
The uses of plasma for syphilis serology should be restricted to (i) specialized laboratories such as blood banks, (ii) field laboratories without centrifugation facilities, or (iii) situations in which a serum sample cannot be obtained. If a plasma is reactive in the RPR card test or the TRUST and confirmation is necessary, we suggest that a serum sample be drawn since the use of plasma for monitoring the efficacy of treatment and for treponemal tests has not been evaluated.
